Biology direct · 2026
Comprehensive multi-omics analysis reveals a fatty acid metabolism gene signature for prognostic assessment and immunotherapy in nasopharyngeal carcinoma, and identifies ABCC1 as a potential novel therapeutic target.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Yang, Zhu Liru, Zhang Qingqing, Chen Xiaojun, Lv Haoyu, Ma Shuhan, Wang Runzhi, Chang Yuanyuan, Sun Yongchu, Chen Kaihua, Li Ling, Zhu Xiaodong
Аннотация
BACKGROUND: Nasopharyngeal carcinoma (NPC) is a subtype of head and neck squamous cell carcinoma characterized by high recurrence and metastasis rates and poor prognosis. Although immune checkpoint inhibitors have emerged as a promising treatment strategy for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), only a few patients have benefitted significantly from them. Lipid metabolism reprogramming plays a crucial role in NPC progression and its interaction with the immune microenvironment. This study aims to establish a prognostic model for NPC based on lipid metabolism-related factors, further explore its association with tumor immunity, and investigate the potential for immunotherapy.
METHODS: Collect GEO datasets(GSE53819 and GSE102349) for differential expression analysis and least absolute shrinkage and selection operator (LASSO) regression to identify prognostic genes and construct a fatty-acid-metabolism-related prognostic model. Survival analyses and time-dependent receiver operating characteristic (ROC) curves were applied to evaluate the predictive performance of the constructed prognostic markers. Furthermore, associations between the derived risk scores and immunological characteristics were systematically evaluated. Following the identification of ABCC1 as a key gene, its expression was validated through RT-qPCR, immunoblotting, and immunohistochemistry (IHC). Its functional role was further investigated using in vitro functional assays, multiplex immunohistochemistry (mIHC), co-culture experiments with CD8⁺ T cells, and in vivo xenograft tumor models in nude mice.
RESULTS: Four genes (ABCC1, CD1D, CYP4B1, and DPEP2) were identified to constr uct a prognostic model associated with fatty acid metabolism. This model revealed significant distinctions in immune infiltration patterns between high-risk and low-risk groups. Specifically, the high-risk group displayed immunosuppressive characteristics, marked by reduced infiltration of CD8⁺T cells. Functional studies demonstrated that ABCC1 promoted NPC cell proliferation, migration, invasion, ROS accumulation, and lipid metabolic reprogramming. Mechanistically, ABCC1 was epigenetically upregulated by the histone acetyltransferase P300 and contributed to CD8⁺ T cell dysfunction and MEK/ERK pathway activation, thereby driving tumor progression.
CONCLUSION: In summary, we established a novel fatty-acid-metabolism-related prognostic model for assessing the prognosis and potential immunotherapy response of NPC patients, as well as for characterizing the immunological features of the tumor microenvironment (TME). Furthermore, ABCC1 emerged as a promising prognostic biomarker associated with immunotherapeutic responsiveness in NPC, warranting further validation.
CLINICAL TRIAL NUMBER: Not applicable.
METHODS: Collect GEO datasets(GSE53819 and GSE102349) for differential expression analysis and least absolute shrinkage and selection operator (LASSO) regression to identify prognostic genes and construct a fatty-acid-metabolism-related prognostic model. Survival analyses and time-dependent receiver operating characteristic (ROC) curves were applied to evaluate the predictive performance of the constructed prognostic markers. Furthermore, associations between the derived risk scores and immunological characteristics were systematically evaluated. Following the identification of ABCC1 as a key gene, its expression was validated through RT-qPCR, immunoblotting, and immunohistochemistry (IHC). Its functional role was further investigated using in vitro functional assays, multiplex immunohistochemistry (mIHC), co-culture experiments with CD8⁺ T cells, and in vivo xenograft tumor models in nude mice.
RESULTS: Four genes (ABCC1, CD1D, CYP4B1, and DPEP2) were identified to constr uct a prognostic model associated with fatty acid metabolism. This model revealed significant distinctions in immune infiltration patterns between high-risk and low-risk groups. Specifically, the high-risk group displayed immunosuppressive characteristics, marked by reduced infiltration of CD8⁺T cells. Functional studies demonstrated that ABCC1 promoted NPC cell proliferation, migration, invasion, ROS accumulation, and lipid metabolic reprogramming. Mechanistically, ABCC1 was epigenetically upregulated by the histone acetyltransferase P300 and contributed to CD8⁺ T cell dysfunction and MEK/ERK pathway activation, thereby driving tumor progression.
CONCLUSION: In summary, we established a novel fatty-acid-metabolism-related prognostic model for assessing the prognosis and potential immunotherapy response of NPC patients, as well as for characterizing the immunological features of the tumor microenvironment (TME). Furthermore, ABCC1 emerged as a promising prognostic biomarker associated with immunotherapeutic responsiveness in NPC, warranting further validation.
CLINICAL TRIAL NUMBER: Not applicable.